ONCAlert | Upfront Therapy for mRCC
Videos  >  

Evaluating Ruxolitinib With Pegylated Interferon Alfa-2a in Myelofibrosis

Jean-Jacques Kiladjian, MD, PhD
Published Online:4:57 PM, Thu January 17, 2019

Jean-Jacques Kiladjian, MD, PhD, head of clinical investigation at Saint Louis Hospital in Paris, discusses the Ruxopeg trial, a phase I/II trial investigating the combination of ruxolitinib (Jakafi) with pegylated interferon alfa-2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF).

Although ruxolitinib provides a clear benefit for patients with MF, it does not affect the disease history, says Kiladjian. Interferon has been shown to induce molecular responses and pathologic responses, but has a high rate of toxicity. The idea for this trial was to use ruxolitinib to offset the toxicity associated with interferon and improve the rate of molecular response and pathologic response. 
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.